London Daily

Focus on the big picture.
Saturday, Jul 26, 2025

Djokovic-backed ‘biotech’ firm’s approach likened to homeopathy

Djokovic-backed ‘biotech’ firm’s approach likened to homeopathy

Exclusive: QuantBioRes says it designs treatments for viral diseases based on electromagnetic frequency
A Danish “biotech” company in which Novak Djokovic holds a majority stake is working on a “frequency” treatment for 1Covid1-19 that an expert says bears similarities to the principles of homeopathy.

The world No 1 men’s tennis player was forced to leave Australia on Sunday after the country’s immigration minister cancelled his visa on the basis that his presence in Australia might risk “civil unrest” as he is a “talisman of anti-vaccination sentiment”.

On Wednesday it emerged Djokovic had acquired an 80% stake in QuantBioRes, the website of which says it designs treatments for viral diseases and resistant bacteria through “predicting the electromagnetic frequency” that can interfere with a virus’s activity.

“At QuantBioRes, we work in utilising unique and novel Resonant Recognition Model … a biophysical model based on findings that certain periodicities/frequencies within the distribution of energies of free electrons along the protein are critical for protein biological function and interaction with protein receptors and other targets,” the website says.

It carries a quote from the Serbian-American scientist Nikola Tesla: “If you wish to understand the universe, think of energy, frequency and vibration.”

Dr Darren Saunders, an Australian biomedical scientist, said the approach described on the QuantBioRes website was reminiscent of homeopathy, an alternative and unproven treatment that claims illness-causing substances can, in minute doses, treat people who are unwell.

Homeopaths claim that by diluting these substances in water or alcohol, the resulting mixture retains an “imprint” of “frequency” of the original substance that triggers a healing response in the body by causing an energetic shift.

Saunders said in his opinion it was “a stretch” for QuantBioRes to call itself a biotech company. “The ‘innovative technology’ they describe on their website does not reflect contemporary understanding of how biochemistry works,” Saunders said. “If any athletes or other potential investors would like advice on not blowing their cash on this stuff, my fees are reasonable.”

The website says the company will “soon start testing different treatment approaches”, but a link encouraging people to “learn more” appeared to be broken when the Guardian attempted to access it. A link to a July 2020 announcement that QuantBioRes would test 1Covid1-19 deactivation mechanisms also appeared to be broken.

Prof Peter Collignon, an infectious diseases physician and antimicrobial resistance expert, said the QuantBioRes website used “fancy terms” without providing any evidence of success of the methods it promoted. “They’ve given nothing in the way of data,” he said. “People are looking out for new molecules all the time, but the website describes a way of finding a new molecule without providing any evidence of success.”

The chief executive of QuantBioRes, Ivan Loncarevic, denied that the methods developed by his company had anything to do with homeopathy, and defended the lack of data on the company’s website.

“What we do has absolutely nothing to do with homeopathy,” he said in an interview. “The theory behind homeopathy is that you can transfer information from a chemical to another substance, such as water. What we do is to develop peptides with specific functionality. This is pure, classical science.

“Of course we are not putting our data on our website for every idiot to look at. We will soon publish an article in a scientific journal that will collect all our clinical testing.”

When asked when the article would be published, Loncarevic said: “With a little luck, in two to three months, after peer review.”

Asked about Saunders’ opinion that it was “a stretch” for QuantBioRes to call itself a biotech company and that the “innovative technology” described on its site did not reflect contemporary understanding of how biochemistry worked, Loncarevic replied: “That’s because we are innovative.”

He said other pioneers in engineering or science, such as Elon Musk and Galileo, had faced similar criticism when first airing their views. On the subject of broken links, he said this was the first time he had heard of the problem and “it’s not [done] on purpose”.
Newsletter

Related Articles

0:00
0:00
Close
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
×